EnChroma Launches International Color Blindness Awareness Month
15.9.2022 05:02:00 EEST | Business Wire | Press release
EnChroma, Inc. – creators of glasses for color blindness – today announced the launch of International Color Blindness Awareness Month. During the entire month of September, EnChroma and over 50 museums, libraries, school districts, state and federal parks, universities, tourism agencies, and Lions and Kiwanis Clubs will make social media posts and publish other communications designed to educate their members, students, communities and/or followers about Color Vision Deficiency (CVD, or “color blindness”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005741/en/
Image courtesy of EnChroma @enchroma
“We are pleased that so many esteemed institutions have joined EnChroma to promote International Color Blindness Month to educate the world about the impact color vision deficiency has on people at work, in school, and in fully appreciating art or the colors of nature,” said Erik Ritchie, CEO of EnChroma. “More awareness will result in fewer daily frustrations for color blind people and more accessibility.”
Color blindness affects one in 12 men (8%) and one in 200 women (.5%); 350 million people worldwide. While people with normal color vision see over one million shades of color, those with Color Vision Deficiency only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red can appear brown. Click here for images depicting color blindness.
The 50+ organizations supporting International Color Blindness Month include:
|
• Georgia O'Keeffe Museum, NM |
• Boston University, MA |
• Faber-Castell, Germany |
|
• North Carolina State University, NC |
• Birmingham Museum of Art, AL |
• Anythink Libraries, CO |
|
• Museum of Contemporary Art Denver |
• Penn State University, Forensic Science Dept., PA |
|
|
• J.N. "Ding" Darling National Wildlife Refuge, FL |
• Fondazione Paolina Brugnatelli, Milan, Italy |
|
|
• Lions Club, District L, NC |
• Clinton-Macomb Public Library, MI |
• Cantigny Park, IL |
|
• Nelson-Atkins Museum of Art, MO |
• School District of New London, WI |
• Nahant Public Library, MA |
|
• Johnson County Public Library, IN |
• Dallas Museum of Art, TX |
• Lions Club, Adams, MN |
|
• RISD, Museum of Art, Rhode Island School of Design, RI |
• St. Johns County Public Libraries, FL |
|
|
• Alfred University, NY |
• Museum of Fine Arts, St. Petersburg, FL |
• i.d.e.a. Museum, AZ |
|
• Central High School (D301), IL |
• Kiwanis Club of Findlay, OH |
• Shelburne Museum, VT |
|
• Glen Ridge Public Library, NJ |
• Lions Club, District I, NC |
• Downers Grove Public Library, IL |
|
• National Museum of Wildlife Art, WY |
• Motlow State Community College, TN |
• Mulvane Art Museum, KS |
|
• Lions Club, District S, NC |
• Albrecht-Kemper Museum of Art, MO |
• Spiva Center for the Arts, MO |
|
• Eye See Color Project, FL |
• Helsingin Optiikka Oy, Finland |
• Plainfield Area Public Library, IN |
|
• Evansville Vanderburgh Public Library, IN |
•Technology Aids for the Blind & Visually Impaired, NC |
|
|
• Lions Club, District O, NC |
• Unique Optiek BV, The Netherlands |
• Lions Club, District N, NC |
|
• Carolyn Campagna Kleefeld Contemporary Art Museum, CA |
• Jonathan Jones Color Blind Fund, AZ |
|
EnChroma encourages other organizations and individuals to promote color blindness awareness anytime in September by posting to social media, websites and other forums using any of the templates located here, and/or images showing the color blind view of various settings here.
EnChroma Color Accessibility Program
EnChroma continues to lead in advocating for “color accessibility” through its EnChroma Color Accessibility Program, in which over 150 organizations participate. The program helps public venues such as schools, state parks, libraries, museums, tourism bureaus, resorts and other organizations loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the color blind.
Through the program, EnChroma donates a pair of glasses to an organization for every pair it purchases. Materials to educate teachers, parents, employers and others about color blindness, and how to support color blind students, children, employees and visitors, are also provided. EnChroma encourages schools to easily and quickly test all students for color blindness using its free online color vision test. Email accessibility@enchroma.com to learn about the program.
EnChroma’s patented lens technology helps people with red-green color blindness see an expanded range of colors and see them more vibrantly, clearly and distinctly. Studies by world-renowned color vision scientists at the University of California, Davis and France’s INSERM Stem Cell and Brain Research Institute, and the University of the Incarnate Word, have demonstrated the effectiveness of EnChroma glasses.
Story Assets for Media
Visit our Media Kit to download user videos, photos of EnChroma glasses and b-roll.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005741/en/
Contact information
Media Contact
Kent Streeb
Vice President of Communications and Partnerships
P: 530.908.9225
kent@enchroma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
